MedTrace Logo

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

NCT00704483 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 321

Last updated 2020-12-19

No results posted yet for this study

Summary

This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis

Conditions

  • Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Interventions

DRUG

SBR759

Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.

DRUG

Sevelamer HCl

0.8 g tid

DRUG

SBR759

1.5 g tid

DRUG

Sevelamer HCl

1.6 g tid

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-08-31

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Finland
  • France
  • Germany
  • Italy
  • Norway
  • Puerto Rico
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704483 on ClinicalTrials.gov